{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T07:52:23Z","timestamp":1712649143115},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T00:00:00Z","timestamp":1550793600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s10157-019-01713-w","type":"journal-article","created":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T06:39:02Z","timestamp":1550817542000},"page":"834-840","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The beneficial effects of renin\u2013angiotensin system inhibitors (RASI) on IgA nephropathy with tubulointerstitial lesions categorized by Oxford classification"],"prefix":"10.1007","volume":"23","author":[{"given":"Takahiro","family":"Kamiyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahito","family":"Moriyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeko","family":"Kumon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Karasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosaku","family":"Nitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,22]]},"reference":[{"key":"1713_CR1","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/ndt\/gfq665","volume":"26","author":"A McGrogan","year":"2011","unstructured":"McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011;26:414\u201330.","journal-title":"Nephrol Dial Transplant"},{"key":"1713_CR2","first-page":"694","volume":"74","author":"J Berger","year":"1968","unstructured":"Berger J, Hinglais N. Intercapillary deposits of IgA\u2013IgG. J Urol Nephrol (Paris). 1968;74:694\u20135.","journal-title":"J Urol Nephrol (Paris)"},{"key":"1713_CR3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0272-6386(88)80023-4","volume":"12","author":"G D\u2019Amico","year":"1988","unstructured":"D\u2019Amico G. Clinical features and natural history in adults with IgA nephropathy. Am J Kidney Dis. 1988;12:353\u20137.","journal-title":"Am J Kidney Dis"},{"key":"1713_CR4","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1681\/ASN.V131142","volume":"13","author":"FW Ballardie","year":"2002","unstructured":"Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol. 2002;13:142\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"1713_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/00365599.1989.11690429","volume":"23","author":"S Rekola","year":"1989","unstructured":"Rekola S, Bergstrand A, Bucht H. IGA nephropathy: a retrospective evaluation of prognostic indices in 176 patients. Scand J Urol Nephrol. 1989;23:37\u201350.","journal-title":"Scand J Urol Nephrol"},{"key":"1713_CR6","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1159\/000045087","volume":"79","author":"P Freese","year":"1998","unstructured":"Freese P, Norden G, Nyberg G. Morphologic high-risk factors in IgA nephropathy. Nephron. 1998;79:420\u20135.","journal-title":"Nephron"},{"key":"1713_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/BF00868251","volume":"8","author":"RJ Hogg","year":"1994","unstructured":"Hogg RJ, Silva FG, Wyatt RJ, Reisch JS, Argyle JC, Savino DA. Prognostic indicators in children with IgA nephropathy-report of the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol. 1994;8:15\u201320.","journal-title":"Pediatr Nephrol"},{"key":"1713_CR8","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1159\/000167171","volume":"6","author":"NW Boyce","year":"1986","unstructured":"Boyce NW, Holdsworth SR, Thomson NM, Atkins RC. Clinicopathological associations in mesangial IgA nephropathy. Am J Nephrol. 1986;6:246\u201352.","journal-title":"Am J Nephrol"},{"key":"1713_CR9","first-page":"191","volume":"41","author":"R Katafuchi","year":"1994","unstructured":"Katafuchi R, Oh Y, Hori K, Komota T, Yanase T, Ikeda K, et al. An important role of glomerular segmental lesions on progression of IgA nephropathy: a multivariate analysis. Clin Nephrol. 1994;41:191\u20138.","journal-title":"Clin Nephrol"},{"key":"1713_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/00005792-199403000-00002","volume":"73","author":"LS Ibels","year":"1994","unstructured":"Ibels LS, Gyory AZ. IgA nephropathy: analysis of the natural history, important factors in the progression of renal disease, and a review of the literature. Medicine (Baltimore). 1994;73:79\u2013102.","journal-title":"Medicine (Baltimore)"},{"key":"1713_CR11","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S0272-6386(00)70191-0","volume":"35","author":"KF To","year":"2000","unstructured":"To KF, Choi PC, Szeto CC, Li PK, Tang NL, Leung CB, et al. Outcome of IgA nephropathy in adults graded by chronic histological lesions. Am J Kidney Dis. 2000;35:392\u2013400.","journal-title":"Am J Kidney Dis"},{"key":"1713_CR12","first-page":"235","volume":"37","author":"H Okada","year":"1992","unstructured":"Okada H, Suzuki H, Konishi K, Sakaguchi H, Saruta T. Histological alterations in renal specimens as indicators of prognosis of IgA nephropathy. Clin Nephrol. 1992;37:235\u20138.","journal-title":"Clin Nephrol"},{"key":"1713_CR13","first-page":"363","volume":"59","author":"G D\u2019Amico","year":"1986","unstructured":"D\u2019Amico G, Minetti L, Ponticelli C, Fellin G, Ferrario F, di Belgioioso BG, et al. Prognostic indicators in idiopathic IgA mesangial nephropathy. Q J Med. 1986;59:363\u201378.","journal-title":"Q J Med"},{"key":"1713_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.5414\/CNP64171","volume":"64","author":"R Nozawa","year":"2005","unstructured":"Nozawa R, Suzuki J, Takahashi A, Isome M, Kawasaki Y, Suzuki S, et al. Clinicopathological features and the prognosis of IgA nephropathy in Japanese children on long-term observation. Clin Nephrol. 2005;64:171\u20139.","journal-title":"Clin Nephrol"},{"key":"1713_CR15","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1159\/000045563","volume":"84","author":"J Mera","year":"2000","unstructured":"Mera J, Uchida S, Nagase M. Clinicopathologic study on prognostic markers in IgA nephropathy. Nephron. 2000;84:148\u201357.","journal-title":"Nephron"},{"key":"1713_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0272-6386(00)70295-2","volume":"35","author":"L Daniel","year":"2000","unstructured":"Daniel L, Saingra Y, Giorgi R, Bouvier C, Pellissier JF, Berland Y. Tubular lesions determine prognosis of IgA nephropathy. Am J Kidney Dis. 2000;35:13\u201320.","journal-title":"Am J Kidney Dis"},{"key":"1713_CR17","first-page":"337","volume":"49","author":"LJ Vleming","year":"1998","unstructured":"Vleming LJ, de Fijter JW, Westendorp RG, Daha MR, Bruijn JA, van Es LA. Histomorphometric correlates of renal failure in IgA nephropathy. Clin Nephrol. 1998;49:337\u201344.","journal-title":"Clin Nephrol"},{"key":"1713_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1159\/000168068","volume":"10","author":"O Bogenschutz","year":"1990","unstructured":"Bogenschutz O, Bohle A, Batz C, Wehrmann M, Pressler H, Kendziorra H, et al. IgA nephritis: on the importance of morphological and clinical parameters in the long-term prognosis of 239 patients. Am J Nephrol. 1990;10:137\u201347.","journal-title":"Am J Nephrol"},{"key":"1713_CR19","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/ki.2009.168","volume":"76","author":"IS Roberts","year":"2009","unstructured":"Working Group of the International Ig ANN, The Renal Pathology S, Roberts IS, Cook HT, Troyanov S, Alpers CE, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009;76:546\u201356.","journal-title":"Kidney Int"},{"key":"1713_CR20","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/ki.2009.243","volume":"76","author":"DC Cattran","year":"2009","unstructured":"Working Group of the International Ig ANN, The Renal Pathology S, Cattran DC, Coppo R, Cook HT, Feehally J, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76:534\u201345.","journal-title":"Kidney Int"},{"key":"1713_CR21","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s10157-016-1258-8","volume":"21","author":"S Hisano","year":"2017","unstructured":"Hisano S, Joh K, Katafuchi R, Shimizu A, Hashiguchi N, Kawamura T, et al. Reproducibility for pathological prognostic parameters of the Oxford classification of IgA nephropathy: a Japanese cohort study of the Ministry of Health, Labor and Welfare. Clin Exp Nephrol. 2017;21:92\u20136.","journal-title":"Clin Exp Nephrol"},{"issue":"5","key":"1713_CR22","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","volume":"91","author":"H Trimarchi","year":"2017","unstructured":"Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017;91(5):1014\u201321.","journal-title":"Kidney Int"},{"key":"1713_CR23","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1053\/j.ajkd.2013.04.021","volume":"62","author":"J Lv","year":"2013","unstructured":"Lv J, Shi S, Xu D, Zhang H, Troyanov S, Cattran DC, et al. Evaluation of the Oxford Classification of IgA nephropathy: a systematic review and meta-analysis. Am J Kidney Dis. 2013;62:891\u20139.","journal-title":"Am J Kidney Dis"},{"key":"1713_CR24","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1007\/s10157-017-1393-x","volume":"21","author":"AB Kaihan","year":"2017","unstructured":"Kaihan AB, Yasuda Y, Katsuno T, Kato S, Imaizumi T, Ozeki T, et al. The Japanese Histologic Classification and T-score in the Oxford Classification system could predict renal outcome in Japanese IgA nephropathy patients. Clin Exp Nephrol. 2017;21:986\u201394.","journal-title":"Clin Exp Nephrol"},{"key":"1713_CR25","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1097\/01.ASN.0000068460.37369.DC","volume":"14","author":"M Praga","year":"2003","unstructured":"Praga M, Gutierrez E, Gonzalez E, Morales E, Hernandez E. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol. 2003;14:1578\u201383.","journal-title":"J Am Soc Nephrol"},{"key":"1713_CR26","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1159\/000013619","volume":"20","author":"T Nakamura","year":"2000","unstructured":"Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Sekizuka K, et al. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy. Am J Nephrol. 2000;20:373\u20139.","journal-title":"Am J Nephrol"},{"key":"1713_CR27","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s10157-015-1195-y","volume":"20","author":"S Tanaka","year":"2016","unstructured":"Tanaka S, Ninomiya T, Katafuchi R, Masutani K, Nagata M, Tsuchimoto A, et al. The effect of renin\u2013angiotensin system blockade on the incidence of end-stage renal disease in IgA nephropathy. Clin Exp Nephrol. 2016;20:689\u201398.","journal-title":"Clin Exp Nephrol"},{"key":"1713_CR28","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.semnephrol.2004.01.005","volume":"24","author":"O Hotta","year":"2004","unstructured":"Hotta O. Use of corticosteroids, other immunosuppressive therapies, and tonsillectomy in the treatment of IgA nephropathy. Semin Nephrol. 2004;24:244\u201355.","journal-title":"Semin Nephrol"},{"key":"1713_CR29","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1007\/s10157-018-1555-5","volume":"22","author":"Y Zou","year":"2018","unstructured":"Zou Y, Yang M, Du X. New insight into the management of IgA nephropathy. Clin Exp Nephrol. 2018;22:1442\u20133.","journal-title":"Clin Exp Nephrol"},{"key":"1713_CR30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1159\/000330189","volume":"34","author":"T Moriyama","year":"2011","unstructured":"Moriyama T, Amemiya N, Ochi A, Tsuruta Y, Shimizu A, Itabashi M, et al. Comparison of steroids and angiotensin receptor blockers for patients with advanced IgA nephropathy and impaired renal function. Am J Nephrol. 2011;34:233\u201340.","journal-title":"Am J Nephrol"},{"key":"1713_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1755-1536-3-7","volume":"3","author":"IM Meer van der","year":"2010","unstructured":"van der Meer IM, Cravedi P, Remuzzi G. The role of renin angiotensin system inhibition in kidney repair. Fibrogenesis Tissue Repair. 2010;3:7.","journal-title":"Fibrogenesis Tissue Repair"},{"key":"1713_CR32","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1007\/s10157-011-0455-8","volume":"15","author":"T Moriyama","year":"2011","unstructured":"Moriyama T, Amamiya N, Ochi A, Tsuruta Y, Shimizu A, Kojima C, et al. Long-term beneficial effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy for patients with advanced immunoglobulin A nephropathy and impaired renal function. Clin Exp Nephrol. 2011;15:700\u20137.","journal-title":"Clin Exp Nephrol"},{"key":"1713_CR33","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1172\/JCI112528","volume":"77","author":"S Anderson","year":"1986","unstructured":"Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Investig. 1986;77:1993\u20132000.","journal-title":"J Clin Investig"},{"key":"1713_CR34","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1046\/j.1523-1755.2000.00031.x","volume":"57","author":"MW Taal","year":"2000","unstructured":"Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int. 2000;57:1803\u201317.","journal-title":"Kidney Int"},{"key":"1713_CR35","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1007\/s10157-016-1239-y","volume":"20","author":"Y Okabayashi","year":"2016","unstructured":"Okabayashi Y, Tsuboi N, Haruhara K, Kanzaki G, Koike K, Shimizu A, et al. Reduction of proteinuria by therapeutic intervention improves the renal outcome of elderly patients with IgA nephropathy. Clin Exp Nephrol. 2016;20:910\u20137.","journal-title":"Clin Exp Nephrol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-019-01713-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-019-01713-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-019-01713-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T10:03:47Z","timestamp":1662977027000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-019-01713-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,22]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["1713"],"URL":"https:\/\/doi.org\/10.1007\/s10157-019-01713-w","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,22]]},"assertion":[{"value":"10 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}